News, Twitter, and LitBot
Announcements
9/25/19: The ASCO Post interviews Center director Andy Minn about the scientific vision of MFCIIR@Penn. Read it here.
11/26/19: Center scientist Jorge Henao-Mejia and Sara Cherry were both honored with Penn Medicine Awards of Excellence. Jorge received the Micheal S. Brown New Investigator Award and Sara received the Stanley N. Cohen Biomedical Research Award.
01/09/20: Congratulations to Costas Koumenis, Lei Dong, and colleagues on their manuscript on Proton FLASH Radiation. See Penn press release. This is one of the first studies describing proton FLASH dosimetry, tumor killing, and sparing of normal GI tissue toxicity.
02/10/20: Read about a FLASH Radiation clinical trial for dogs with bone cancer conducted by the Penn School of Veterinary Medicine and the Perelman School of Medicine.
08/01/21: New paper from Center investigators Dr. Andy Minn and Dr. Carl June, on The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function. See Penn press release. This work describes a new kind of CAR-T cell with enhanced function AND the ability to recruit the body’s own endogenous T cells in order to reject tumors typically resistant to CAR-T cell therapy.
03/06/22: NIH P01 awarded to Penn to study and develop FLASH radiation. See Penn press release. Center investigator Costas Koumenis will help lead a multi-disciplinary and international group of scientists from Penn, Duke, Oxford University, and University of Heidelberg.
-
RT @Tcellogic: Hi all- I’m looking for postdocs to work on neuro inflammation, aging and Alzheimer’s disease. It’s a bold and visi… https://t.co/FB9eRR3685
-
RT @UPenn_I3H: Congratulations @BrodskyIgor, Robert R. Marshak Professor and Chair of the Department of Pathobiology, as the recip… https://t.co/L7NYpjLIUw
-
Nice analysis and study, @ScienceChow! My grad school mentor once told me if your data goes one way and dogma or co… https://t.co/CB4BvxTKUY
-
RT @moorejh: Retaining postdocs by recognizing their worth https://t.co/TvUSrMz9oU #postdoc #sciencetwitter
-
RT @TheMarkFdn: Celebrating #WomenInScienceDay by featuring these @TheMarkFdn Scientific Symposium 2022 speakers! These leading sci… https://t.co/qB2xbtDMJP
Immunotherapy Literature Bot
Automated literature searches of select journals and BioRxiv.
-
ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer https://t.co/cEEy6Y7K4p
-
Q&A: Robert Vonderheide on Immunotherapy Advances https://t.co/tL6Zil6ZWG https://t.co/spdpNWv000
-
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial https://t.co/SZANdmk0WY https://t.co/I3KqMiQyg7
-
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans https://t.co/mJvRL0gKFH https://t.co/m40wdaMzRj
-
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction… https://t.co/s12fsSSWpB